- Assistant Professor, Department of Global Health, Amsterdam UMC, University of Amsterdam
- Honorary Professor, Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, United Kingdom
- Professor of Public and Population Health, Faculty of Medicine, McGill University, Canada
- Member of COVID-19 Immunity Task Force, Canada
Dr. Catherine Hankins BA (Hons) & MD (Calgary), MSc (London, UK), PhD (Amsterdam), FRCPC (Community Medicine) was Chief Scientific Adviser to UNAIDS in Geneva during 2002-2012. She led the scientific knowledge translation team focused on ensuring ethical and participatory biomedical HIV prevention trial conduct, convening mathematical modelling teams, and supporting country implementation of proven biomedical HIV prevention modalities. Currently, she chairs the Scientific Advisory Committee of the European and Developing Countries Clinical Trials Partnership and the Scientific Advisory Group of the USA National Institutes of Health HIV Prevention Trials Network. She is a Good Participatory Practice (GPP) Advisory Committee member for the USAID-funded Coalition to Accelerate and Support Prevention Research (CASPR). She is a trustee of the HIV Research Trust that awards short-term scholarships to early and mid-career health professionals in resource-limited settings and a member of the Organising Committee for the annual Netherlands NCHIV. She was the Lead Rapporteur for Implementation Science at the International AIDS Society (IAS) 2017 conference in Paris and is Track D co-chair (Social and Political Research, Law, Policy, and Human Rights) for Amsterdam’s IAS 2018.
Since 2014, Dr. Hankins has been Scientific Chair and Organising Committee Chair of AIGHD’s INTEREST conference [Harare, Zimbabwe 2015; Yaoundé, Cameroon, 2016; Lilongwe, Malawi, 2017; and Kigali, Rwanda, 2018]. Previously, she was principal investigator of ‘The Canadian Women’s HIV Study’, research involving prisoners and people who inject drugs, and population-based epidemiological studies. Her current scientific interests include implementation science, novel biomedical HIV prevention, women and HIV, and participatory research conduct. She is the AIGHD co-Principal Investigator for the CAPRISA 012 trial of a sustained-release tenofovir alafenamide sub-dermal implant for HIV prevention in women. Recently, she developed GPP Guidelines for trials of Emerging Pathogens for the World Health Organization.
Male circumcision cuts sexually transmitted infections and cervical cancer risk in women.
Morris B and Hankins C.
The Lancet Global Health 2017; 5 (11), pages e1054–e1055.
Scientific Developments from the 2016 INTEREST Conference, Yaoundé, Cameroon May 3-6, 2016.
Hankins C, Koulla-Shiro S, Kilmarx PH, Ferrari G, Schechter M, Toure Kane NC, Venter F, Boucher C, Zewdie D, Eholié S, Katabira E.
Antiviral Therapy 2017; 22:179-184. DOI 10.3851
Voluntary Medical Male Circumcision for HIV Prevention: New Mathematical Models for Strategic Demand Creation Prioritizing Subpopulations by Age and Geography.
Hankins C, Warren M, Njeuhmeli E.
PLoS One. 2016 Oct 26;11(10):e0160699. doi: 10.1371/journal.pone.0160699. PMID: 27783613
Translating PrEP effectiveness into public health impact: key considerations for decision-makers on cost-effectiveness, price, regulatory issues, distributive justice, and advocacy for access.
Hankins C, Macklin R, Warren M.
JIAS, July 2015, 18(Suppl 3):19973
The promise of pre-exposure prophylaxis with antiretroviral drugs to prevent HIV transmission: a review.
Hankins CA, Dybul MR.
Curr Opin HIV AIDS. 2013 Jan;8(1):50-8. PMID: 23201856